Sales was +3% in local currencies excluding discontinued business, 0% in local currencies. Total sales amounted to 871 MSEK (941), significantly impacted by currency. Despite economic uncertainties we have remained resilient delivering growth by taking share.
Latest financial report
Interim report Q2, 2025: Strong performance across Consumables
Sales was +3% in local currencies excluding discontinued business, 0% in local currencies. Total sales amounted to 871 MSEK (941), significantly impacted by currency. Despite economic uncertainties we have remained resilient delivering growth by taking share.
Vitrolife Group acquires eFertility
An innovative system and software company transforming IVF clinic management with cutting edge solutions
We are delighted to announce that the Vitrolife Group successfully completed the acquisition of eFertility (STB Zorg B.V.). This acquisition is a key element of the Vitrolife Group’s strategy to bring increased standardisation and digitalisation to IVF clinics around the world.
“The acquisition of eFertility represents a significant step in the Vitrolife Group’s strategy to transform and digitalise the IVF patient journey. By incorporating eFertility’s technologies into our platform, we are making critical advancements towards the development of a seamlessly integrated and more efficient clinic workflow." said Bronwyn Brophy O´Connor, CEO of Vitrolife Group.
Capital Markets Day 2023
The Vitrolife Group hosted a Capital Markets Day where we shared details of our future vision for reproductive health, our strategic plan for the company and the role we want to play in bringing more innovation to market and helping increase capacity and access for patients.
If you missed it, you can log in and see the recording under resources.
Excellence in reproductive health
By combining Igenomix’s reproductive genetic testing services with Vitrolife’s IVF medical devices, we are now better than ever positioned to serve our customers and their patients, so that more families can fulfil the dream of having a healthy baby.
Reasons to invest in Vitrolife Group
- Underlying resilient market growth.
- High quality brands linked with outstanding service and support.
- Proven track record of profitable growth.
- Innovation and technology leader within fertility.
- Ambitious strategy and long-term objectives.
Press Releases
Financial Calendar
-
23 Oct 2025
Interim report Q3, 2025
-
03 Feb 2026
Fourth quarter and full year report 2025
-
23 Apr 2026
Interim report Q1, 2026
The Nasdaq OMX Sweden Small Cap 30 ESG Responsible™ Index
Vitrolife Group included in the new Nasdaq OMX Sweden Small Cap 30 ESG Responsible Index™
Annual and sustainability report 2024
One year into our corporate strategy
In 2024, the Vitrolife Group achieved key milestones in our corporate strategy, to advance our mission of becoming the leading global partner in reproductive health, striving for better treatment outcomes for patients. We invested in our key strategic pillars of growth, innovation and operational excellence to prepare our company to support sustainable profitable growth in the long-term. In addition, we increased our focus in the largest IVF markets in the world namely the US and China. Investments in talent, culture and sustainability, our key enablers have also been a focus for the company throughout the year.
IR Contact
Amelie Wilson
Welcome to contact us if you have questions about the Vitrolife Group in relation to investments and the listing on Nasdaq Stockholm.
Financial Reports
Read Vitrolife Group's financial reports, including the latest release of the annual and sustainability report and interim reports.
Sustainability
Ensuring sustainability in everything we do is one of our key strategic priorities. Learn more on our approach and sustainability themes.
Corporate governance
Vitrolife AB is a publicly traded Swedish company listed on NASDAQ Stockholm. The company's corporate governance policies comply with Swedish laws and regulations.